The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
Abstract
PURPOSE: Amplification and/or overexpression of the HER-2/neu oncogene have been shown to correlate with poor clinical outcome in patients with axillary node-positive breast cancer. In contrast, the prognostic significance of HER-2/neu in node-negative disease is controversial. This study was undertaken to evaluate further the relationship between HER-2/neu and clinical outcome in node-negative disease. PATIENTS AND METHODS: Overexpression of HER-2/neu was evaluated by permanent-section immunohistochemistry in tumors from 613 patients with long-term clinical follow-up enrolled in the Intergroup Study 0011. Patients were stratified into low-risk (n = 307) and high-risk (n = 306) groups on the basis of tumor size and estrogen-receptor (ER) status. Low-risk patients were defined as having small (less than 3 cm), ER-positive tumors and were observed without additional treatment after initial surgery. High-risk patients had either ER-negative or large (greater than or equal to 3 cm), ER-positive tumors and were randomized to be observed (n = 146) or to receive adjuvant chemotherapy (n = 160) after surgery. RESULTS: The rate of HER-2/neu overexpression was 14.3% in all tumors combined and was higher in invasive carcinomas with (21.5%) than without (11.2%) a significant noninvasive or in situ histologic component (P less than .0001). There was no relationship between overexpression and clinical outcome in the natural history setting of combined low-risk and high-risk patients not receiving adjuvant therapy (n = 453). Based on the reasoning that the influence of HER-2/neu may have been obscured by high-risk features and/or the presence of noninvasive carcinoma, we also analyzed the subset of patients with low-risk lesions not containing a significant in situ component (n = 179). Patients of this group with HER-2/neu-positive tumors showed only 40% disease-free survival (DFS) at 5 years, compared with over 80% in patients with HER-2/neu-negative tumors (P less than .0001). A similar inverse correlation was observed between overexpression and overall survival in the same group of patients (P = .0001). In a separate analysis involving patients receiving adjuvant chemotherapy, those with HER-2/neu-negative tumors showed significantly improved DFS in response to therapy compared with patients with HER-2/neu-positive tumors. CONCLUSION: Overexpression of HER-2/neu is associated with poor clinical outcome in a subset of node-negative patients with small, ER-positive, predominantly invasive tumors and may play a role in resistance to adjuvant chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationEvaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Diagnostic Histopathology of the Breast
Page, D. L., & Anderson, T. J. (1988) · Medical Entomology and Zoology · Cited by 1,064
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 622
Semba, K., Kamata, N., Toyoshima, K., & Yamamoto, T. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6497 · Cited by 598
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., & McGuire, W. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1120 · Cited by 574
Self-citationPrediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow Cytometry
Clark, G. M., Dressler, L. G., Owens, M. A., Pounds, G., Oldaker, T., & McGuire, W. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201003 · Cited by 558
Self-citationHER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg, Å., Tandon, A., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., & Wl, M. (1990) · PubMed · Cited by 554
Self-citationSchechter, A. L., Hung, M.-C., Vaidyanathan, L., Weinberg, R. A., Yang-Feng, T. L., Francke, U., Ullrich, A., & Coussens, L. (1985) · Science · doi:10.1126/science.2992090 · Cited by 518
Varley, J. M., Swallow, J. E., Brammar, W. J., Whittaker, J. L., & Walker, R. A. (1987) · PubMed · Cited by 360
Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer
Mansour, E. G., Gray, R., Shatila, A. H., Osborne, C. K., Tormey, D. C., Gilchrist, K. W., Cooper, M. R., & Falkson, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200803 · Cited by 352
Self-citationTsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Yamamoto, H., Miyajima, N., Toyoshima, K., Yamamoto, T. S., & Yokota, J. (1989) · PubMed · Cited by 341
Gullick, W., Love, S., Wright, C., Barnes, D., Gusterson, B., Harris, A., & Altman, D. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.100 · Cited by 327
Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., LEES, A. W., Jamil, N. S. M., Hanson, J., Jenkins, H., Krause, B. E., & McBlain, W. A. (1991) · PubMed · Cited by 296
Direct Interaction of a Ligand for the erb B2 Oncogene Product with the EGF Receptor and p185 erb B2
Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., & Lippman, M. E. (1990) · Science · doi:10.1126/science.2218496 · Cited by 277
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I., Locker, A., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237
Amplification of c-erb B-2 and Aggressive Human Breast Tumors?
Ali, I. U., Campbell, G., Lidereau, R., & Callahan, R. (1988) · Science · doi:10.1126/science.3289120 · Cited by 236
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
Zhou, D., Battifora, H. A., Yokota, J., Yamamoto, T. S., & Cline, M. J. (1987) · PubMed · Cited by 209
c-erbB-2 expression in benign and malignant breast disease
Gusterson, B., Machin, L., Gullick, W., Gibbs, N., Powles, T., Elliott, C., Ashley, S., Monaghan, P., & Harrison, S. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.239 · Cited by 190
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
O'Reilly, S., Barnes, D. M., Camplejohn, R., Bártková, J., Gregory, W. M., & Richards, M. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.102 · Cited by 130
Adjuvant Therapy of Node-Negative Breast Cancer
McGuire, W. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200811 · Cited by 125
Zhou, D. J., Ahuja, H., & Cline, M. J. (1989) · PubMed · Cited by 125
Mizukami, Y., Nonomura, A., Yamada, T., Kurumaya, H., Hayashi, M., KOYASAKI, N., Taniya, T., Noguchi, M., Nakamura, S., & Matsubara, F. (1990) · PubMed · Cited by 65
c-erbB-2 protein expression in node negative breast cancer
Richner, J., Gerber, H., Locher, G. W., Goldhirsch, A., Gelber, R. D., Gullick, W. J., Berger, M. S., Groner, B., & Hynes, N. E. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057745 · Cited by 35
Cited by
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationHarris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationRoss, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Metadata
- Authors
- Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-04
- Volume
- 10
- Issue
- 4
- Pages
- 599-605
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1871768557
- Cited by
- 456
- References
- 32
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.